Hansoh Pharmaceutical

NCT02746302

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HS-20004 in Healthy Chinese Volunteers

NCT01985152

A Phase Ⅰa Study of Azilsartan Trimethylethanolamine in Healthy Volunteers

NCT02140606

Phase I Trial to Investigate Cafusertib Hydrochloride in Combination With Low Dose Cytarabine in Chinese Patients With Acute Myeloid Leukaemia (AML)

NCT02619097

Safety & Pharmacokinetics of Pegolsihematide for Treatment of Anemia Patient With Myelodysplastic Syndromes

NCT02746315

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple s.c Doses HS-20004 in Healthy Chinese Volunteers

NCT02314884

Phase I Trial to Investigate Cafusertib Hydrochloride Monotherapy in Chinese Patients With Advanced Solid Tumours

NCT02467790

Polyethylene Glycol Loxenatide Pharmacokinetics Study in Subjects With Normal and Insufficiency Renal Function

NCT02447601

Evaluate the Pharmacokinetics of Simvastatin When Coadministered With PEX168 in Healthy Adult Subjects

NCT02472236

Evaluate the Pharmacokinetics of Digoxin When Coadministered With PEX168 in Healthy Adult Subjects

NCT02461914

Evaluate the Pharmacokinetics of Warfarin When Coadministered With PEX168 in Healthy Adult Subjects

NCT02750007

Tolerability to HS-20004 With Titration Administration in Type 2 Diabetic Patients

NCT02977364

A Trial of C-met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumours

NCT03243643

Tolerability, Safety, Pharmacokinetics and Efficacy of HS-10241 Single Agent or Combined With Apatinib in Patients With Advanced Solid Tumors

NCT04060511

A Study of HS-10342 in Patients With Advanced Solid Tumor

NCT04477057

PhaseⅠStudy of the HS-10241 in Patients With Advanced Solid Tumors

NCT04477096

Evaluation of Drug Interaction Between HS-10234 and Emtriccitabine

NCT04494373

Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of HS-20090 and Xgeva® in Healthy Adults

NCT04631835

Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer

NCT04881006

Bioequivalence of Dapagliflozin 10 mg Tablets Under Fed Conditions

NCT04880993

Bioequivalence of Dapagliflozin 10 mg Tablets Under Fasting Conditions

NCT04652297

Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Administration of HS-10356 in Healthy Volunteers

NCT05195203

A Study of HS-10353 in Chinese Participants.

NCT04986436

Phase I Study to Evaluate Safety, Tolerability, and Pharmacokinetics of HS-10360 in Healthy Subjects.

NCT05196971

A Study To Evaluate The Safety, Tolerability And Pharmacokinetics of HS-10345 In Treatment-Resistant Depression

NCT05116410

A Study of HS-20094 in Healthy Participants

NCT06033742

A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10374 in Healthy Subjects

NCT05430386

Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC

NCT05504213

A Phase Ib Study of HS-10352 Plus Fulvestrant in Patients With Advanced Breast Cancer

NCT05429723

First-in-Human Study to Investigate the Safety and Tolerability and Pharmacokinetics of HS-10383

NCT05367700

A Study of HS-10382 in Patients With Chronic Myeloid Leukemia.

NCT05378178

A PhaseⅠStudy of HS-10381 in Patients With Advanced Solid Tumors

NCT05480592

A Study of HS-10380 in Chinese Participants

NCT05911464

A Phase I Study of HS-10386 in Participants With Advanced Solid Tumors

NCT05777109

Comparing of the PK, PD, Safety and Immunogenicity of HS-20090 and Xgeva® in Healthy Adults

NCT05740956

A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors

NCT06092983

A Multiple-Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of HS-10383

NCT05953506

Phase 1a Study in Healthy Participants

NCT06049030

A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma

NCT06118827

A Study of HS-10518 in Healthy Female Participants

NCT06210607

A Trial of HS-10511 in Healthy Subjects

NCT06359600

A Study of HS-10501 Tablets in Healthy Subjects

NCT06301074

The Phase I Study of HS-10509 in Chinese Adult Subjects

NCT06383897

Phase 1 Study in Healthy Participants and Participants With Kidney Dysfunction

NCT06553339

A Study of HS-10516 in Patients With VHL Syndrome Associated Tumors

NCT06530810

Study of HS-10382 Combination in Patients With Chronic Myeloid Leukemia (CML)

NCT06554548

A Study Evaluating Food Effect on Pharmacokinetics of HS-10518

NCT06594874

A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors

NCT07130916

A Study of Aumolertinib in European Participants With Non-Small Cell Lung Cancer

NCT06926413

A Study Evaluating the Effect of Aumolertinib on the Pharmacokinetics of Midazolam in Patients With NSCLC

NCT06823245

Pharmacokinetic Study of HS-10241 Tablets in Subjects with Hepatic Impairment and Normal Hepatic Function

NCT06823258

Pharmacokinetic Study of HS-10365 Capsule in Subjects with Hepatic Impairment and Normal Hepatic Function

NCT07057674

A Study of HS-20094 in Overweight or Obese Participants

NCT06846710

Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118

NCT06769425

HS-10502 Combination Treatment in Patients With Advanced Solid Tumors

NCT06963398

A Study of HS-10529 in KRAS G12D Patients With Advanced Solid Tumors

NCT07033234

Evaluate the Safety and Pharmacokinetics/Pharmacodynamics and Food Effect of HS-20118

NCT07040046

HS-10542 Study in Healthy Participants

NCT06963502

A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors

NCT07001787

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HS-10510 in Healthy Subjects

NCT06461156

A Study of HS-10504 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)